X4 Pharmaceuticals Presents Phase 3 Trial Plans for Mavorixafor
X4 Pharmaceuticals presented plans for a Phase 3 trial of mavorixafor in primary chronic neutropenia.
X4 Pharmaceuticals presented plans for a Phase 3 trial of mavorixafor in primary chronic neutropenia.